Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3861872 | 1.00 | MEN1 (0.43) | MEN1KMT2AGAAALOX5SMN1; SMN2 | |
| SCHEMBL3862770 | 0.83 | CISD1 (0.41) | MEN1KMT2AGAAALOX5HTT | |
| SCHEMBL3866428 | 0.83 | CISD1 (0.41) | MEN1KMT2AGAAALOX5HTT | |
| SCHEMBL3864864 | 0.82 | EGFR (0.46) | MEN1KMT2AALOX5SMN1; SMN2HTT | |
| SCHEMBL3865230 | 0.82 | EGFR (0.46) | MEN1KMT2AALOX5SMN1; SMN2HTT | |
| SCHEMBL4157222 | 0.77 | CISD1 (0.41) | MEN1KMT2AALOX5HTTCISD1 | |
| SCHEMBL4157218 | 0.77 | CISD1 (0.41) | MEN1KMT2AALOX5HTTCISD1 | |
| SCHEMBL3861864 | 0.76 | MEN1 (0.44) | MEN1KMT2AALOX5SMN1; SMN2CISD1 | |
| SCHEMBL3864238 | 0.75 | CLK1 (0.35) | MEN1KMT2AALOX5HTTMAPK1 | |
| SCHEMBL3874063 | 0.75 | CLK1 (0.35) | MEN1KMT2AALOX5HTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501428-B2 | e.g. 2-(1-hydroxymethyl-2-phenyl-ethylamino)-5-[1-quinazolin-6-yl-methylidene]-thiazol-4-one; cyclin-dependent kinases (CDKs)/serine-threonine protein kinases inhibitor; antiproliferative, anticarcinogenic, antitumor agent | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | claimed |
| EP-1802614-A1 | QUINAZOLINYLMETHYLENETHIAZOLINONES AS CDK1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-07-04 | — | — | EP | claimed |
| WO-2006040050-A1 | QUINAZOLINYLMETHYLENE THIAZOLINONES AS CDK1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | WO | claimed |
| US-20060084804-A1 | Quinazoline thiazolinones | CHEN LI | 2006-04-20 | — | — | US | claimed |
| US-7501428-B2 | e.g. 2-(1-hydroxymethyl-2-phenyl-ethylamino)-5-[1-quinazolin-6-yl-methylidene]-thiazol-4-one; cyclin-dependent kinases (CDKs)/serine-threonine protein kinases inhibitor; antiproliferative, anticarcinogenic, antitumor agent | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501428-B2 | e.g. 2-(1-hydroxymethyl-2-phenyl-ethylamino)-5-[1-quinazolin-6-yl-methylidene]-thiazol-4-one; cyclin-dependent kinases (CDKs)/serine-threonine protein kinases inhibitor; antiproliferative, anticarcinogenic, antitumor agent | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501428-B2 | e.g. 2-(1-hydroxymethyl-2-phenyl-ethylamino)-5-[1-quinazolin-6-yl-methylidene]-thiazol-4-one; cyclin-dependent kinases (CDKs)/serine-threonine protein kinases inhibitor; antiproliferative, anticarcinogenic, antitumor agent | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1802614-A1 | QUINAZOLINYLMETHYLENETHIAZOLINONES AS CDK1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040050-A1 | QUINAZOLINYLMETHYLENE THIAZOLINONES AS CDK1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | WO | disclosed |
| US-20060084804-A1 | Quinazoline thiazolinones | CHEN LI | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084804-A1 | Quinazoline thiazolinones | CDK1, CDK14, CDK18 | MEN1 1847/4885KMT2A 1225/4885GAA 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.